PL372055A1 - Leczenie nadciśnienia u kobiet poddawanych hormonalnej terapii zastępczej - Google Patents

Leczenie nadciśnienia u kobiet poddawanych hormonalnej terapii zastępczej

Info

Publication number
PL372055A1
PL372055A1 PL03372055A PL37205503A PL372055A1 PL 372055 A1 PL372055 A1 PL 372055A1 PL 03372055 A PL03372055 A PL 03372055A PL 37205503 A PL37205503 A PL 37205503A PL 372055 A1 PL372055 A1 PL 372055A1
Authority
PL
Poland
Prior art keywords
hypertension
treatment
replacement therapy
hormone replacement
women receiving
Prior art date
Application number
PL03372055A
Other languages
English (en)
Inventor
Adel H. Karara
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of PL372055A1 publication Critical patent/PL372055A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL03372055A 2002-04-26 2003-03-24 Leczenie nadciśnienia u kobiet poddawanych hormonalnej terapii zastępczej PL372055A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37543902P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
PL372055A1 true PL372055A1 (pl) 2005-07-11

Family

ID=29270642

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372055A PL372055A1 (pl) 2002-04-26 2003-03-24 Leczenie nadciśnienia u kobiet poddawanych hormonalnej terapii zastępczej

Country Status (23)

Country Link
US (1) US20040034001A1 (pl)
EP (2) EP1499323A1 (pl)
JP (1) JP2005528408A (pl)
KR (1) KR20040104632A (pl)
CN (1) CN1649596A (pl)
AU (2) AU2003239162A1 (pl)
BR (1) BR0309780A (pl)
CA (1) CA2483554A1 (pl)
CR (1) CR7571A (pl)
EC (1) ECSP045456A (pl)
HK (1) HK1079997A1 (pl)
HR (1) HRP20041121A2 (pl)
IL (1) IL164808A0 (pl)
ME (1) MEP35908A (pl)
MX (1) MXPA04010682A (pl)
NO (1) NO20045147L (pl)
NZ (1) NZ548754A (pl)
PL (1) PL372055A1 (pl)
RS (1) RS93804A (pl)
RU (1) RU2373940C2 (pl)
UA (1) UA87437C2 (pl)
WO (1) WO2003090755A1 (pl)
ZA (1) ZA200409548B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DE102004016779A1 (de) * 2004-04-01 2006-01-19 Schering Ag Drospirenonhaltige Zubereitungen zur transdermalen Anwendung
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
US20090035373A1 (en) * 2007-07-31 2009-02-05 Katrin Mittmann Pharmaceutical composition for contraception and blood pressure regulation, kit for contraception containing same and method of production of same
US20090035374A1 (en) * 2007-07-31 2009-02-05 Katrin Mittmann Method of making a single-stage pharmaceutical preparation for oral therapy to regulate blood pressure and kit containing same
KR20130097073A (ko) * 2010-04-15 2013-09-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 초저-용량의 ｈｒｔ용 고체 경구 투여 형태
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2648470C2 (ru) * 2016-03-03 2018-03-26 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US5001113A (en) 1987-10-14 1991-03-19 Merck & Co., Inc. Di- or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
US6083528A (en) 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
KR0156678B1 (ko) 1996-01-11 1998-10-15 이상윤 안지오텐신 전환효소 저해제
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
DK1380301T3 (da) * 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
AU2001225413B2 (en) * 2000-01-18 2005-06-23 Bayer Schering Pharma Aktiengesellschaft Drospirenone for hormone replacement therapy
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins

Also Published As

Publication number Publication date
MEP35908A (en) 2011-02-10
MXPA04010682A (es) 2004-12-13
KR20040104632A (ko) 2004-12-10
WO2003090755A1 (en) 2003-11-06
HK1079997A1 (zh) 2006-04-21
NO20045147L (no) 2005-01-18
CR7571A (es) 2006-02-07
AU2008203497A1 (en) 2008-08-28
IL164808A0 (en) 2005-12-18
BR0309780A (pt) 2005-03-22
UA87437C2 (ru) 2009-07-27
NZ548754A (en) 2008-06-30
EP1499323A1 (en) 2005-01-26
HRP20041121A2 (en) 2005-02-28
US20040034001A1 (en) 2004-02-19
ZA200409548B (en) 2010-05-26
AU2003239162A1 (en) 2003-11-10
ECSP045456A (es) 2005-01-28
RU2373940C2 (ru) 2009-11-27
CN1649596A (zh) 2005-08-03
RU2004134571A (ru) 2005-07-10
EP1982719A1 (en) 2008-10-22
CA2483554A1 (en) 2003-11-06
RS93804A (sr) 2006-10-27
JP2005528408A (ja) 2005-09-22

Similar Documents

Publication Publication Date Title
ZA200409548B (en) Treatment of hypertension in women receiving hormone replacement therapy
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
EP1404343A4 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES
AU2003261251A1 (en) Methods of delivering therapeutic agents
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
ZA200410401B (en) Use of thio-oxindole derivatives in treatment of skin disorders
ZA200308027B (en) Hormone replacement therapy
EP1494678A4 (en) hormone therapy PROCEDURE
ZA200402944B (en) Vaginally administered anti-dysrhythmic agents for treating pelvic pain and infertility
GB0223367D0 (en) Therapeutic treatment
GB0223854D0 (en) Therapeutic treatment
GB0211295D0 (en) Treatment of pain
AU2003217971A8 (en) Gas-plasma treatment of implants
PL397023A1 (pl) Środek leczniczy do leczenia AIDS
IL166062A0 (en) Compositions and methods for therapeutic treatment
GB0210464D0 (en) Therapeutic treatment
HUP0401589A3 (en) New peptides - analogs of human growth hormone-releasing hormone
EP1494750A4 (en) STIMULATION OF MUSCLES IN A IMMOBILIZED MEMBER IN A PLASTER
AU2003270615A8 (en) Treatment of steatosis using hyperthermia
EP1583543A4 (en) METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA
AU2003265867A8 (en) A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
AU2003280320A1 (en) Human growth hormone treatment methods

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)